A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
← catalyst calendarSponsored by Xencor, Inc. (industry) · XNCR — their whole pipeline →. With ICON plc.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
170estimated
Sites
17
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-21 | actual | When the study began enrolling |
| Primary completion | 2025-10-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Clear Cell Carcinoma
- Endometrial Cancer
- Cervical Carcinoma
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Intervention
- Biological: vudalimab
Primary outcome
what the primary-completion date above is the date OFPSA50 is the primary endpoint for the mCRPC cohort. Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumours (RECIST) version 1 criteria is the primary endpoint for gynecological malignancy cohorts
measured 12 weeks
Publications
- PMID 39990653 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · XNCR's whole pipeline · Catalyst calendar · Every registered study · What changed